GXAI · Gaxos.ai Inc.

Despite the topline surge, operating income deteriorated to -$2.5 million from -$1.4 million, a -83.0% change. The increase in loss from operations was due to an increase in compensation and related benefits, an increase in advertising and marketing expense, an increase in general and administrative expenses, and an increase in professional fees, offset by the increase in revenues. These dynamics highlight aggressive investments to promote RNK Health and Gaxos Labs while building platform capabilities.

Net income followed suit at -$2.2 million, -82.3% from -$1.2 million last year, with diluted EPS at -$0.25 versus -$0.17. Operating margin stood at -140.8%, underscoring the early-stage economics where development and go-to-market costs outpaced revenue ramp.

General and administrative expenses rose, primarily attributable to an increase in amortization expense, an increase in merchant fees, and an increase in software and application fees, offset by a decrease in other G&A expenses. Development costs also increased primarily due to outside development on Gaxos Labs, Gaxos Health, and RNK Health platforms, fueling R&D intensity.

Cash flow from operating activities reflected heightened burn at -$2.5 million, compared to -$1.3 million prior year, consistent with investment phase dynamics. This was offset in the period by financing activities, though not detailed here.